Beam Therapeutics (BEAM) Stock Price, News & Analysis

Company Overview

Beam Therapeutics, Inc. (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R. Liu, Ph.D., and a team of genome-editing pioneers. Unlike traditional CRISPR/Cas9 approaches that create double-strand DNA breaks, Beam’s base editing platform converts one DNA letter into another through targeted enzymatic reactions, minimizing genomic disruption. The company’s pipeline includes ex vivo programs for monogenic blood disorders such as sickle cell disease and beta thalassemia, as well as in vivo candidates aimed at rare metabolic and genetic conditions. Strategic collaborations with major pharmaceutical partners support the translation of these programs into clinical development.

Since its initial public offering in early 2020, Beam Therapeutics has expanded its capabilities in research, development and manufacturing, forging partnerships to scale delivery and production of its novel editors. The company’s leadership team brings together seasoned executives and scientists with expertise in protein engineering, lipid nanoparticle delivery and regulatory strategy, all united by a commitment to advance next-generation precision therapies. As Beam progresses key programs toward clinical milestones, it remains focused on translating base editing innovations into safe and effective treatments for patients worldwide.

Key Stats

• Today's Range: $25.71 to $26.88
• 50-Day Range: $25.07 to $37.92
• 52-Week Range: $15.60 to $38.26
• Volume: 1.23 million shs
• Average Volume: 1.76 million shs
• Market Capitalization: $2.76 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.00
• Consensus Rating: Moderate Buy

Beam Therapeutics Stock Analysis - MarketRank™

Beam Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 732nd out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Beam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Beam Therapeutics has a consensus price target of $49.00, representing about 83.2% upside from its current price of $26.75.

Amount of Analyst Coverage

Beam Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Beam Therapeutics are expected to decrease in the coming year, from ($4.49) to ($5.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beam Therapeutics is -31.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beam Therapeutics is -31.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beam Therapeutics has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.65% of the float of Beam Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Beam Therapeutics has a short interest ratio ("days to cover") of 11.31, which indicates bearish sentiment.

Change versus previous month

Short interest in Beam Therapeutics has recently increased by 1.22%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beam Therapeutics does not currently pay a dividend.

Dividend Growth

Beam Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.28

News Sentiment

Beam Therapeutics has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 7 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.

MarketBeat Follows

8 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,468,500.00 in company stock.

Percentage Held by Insiders

3.80% of the stock of Beam Therapeutics is held by insiders.

Percentage Held by Institutions

99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 8/15/2026
• Status update: 9/08/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BEAM
• CIK: 1745999
• Web: www.beamtx.com
• Phone: 857-327-8775
• Fax: N/A
• Employees: 510
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Beam Therapeutics: $49.00
• High Price Target: $80.00
• Low Price Target: $26.00
• Potential Upside/Downside: +83.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.99 million
• Net Margins: -54.75%
• Pretax Margin: -55.45%
• Return on Equity: -30.71%
• Return on Assets: -24.07%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 14.57
• Quick Ratio: 14.57

Sales & Book Value

• Annual Sales: $156.04 million
• Price / Sales: 17.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.34 per share
• Price / Book: 2.59

Miscellaneous

• Outstanding Shares: 103,288,000
• Free Float: 99,363,000
• Market Cap: $2.76 billion
• Optionable: Optionable
• Beta: 2.23